AUA 2017: Late-Breaking Abstract – Interim results from a single-arm multicenter Phase II trial of CG0070, an oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC)
Boston, MA (UroToday.com) Despite the recent excitement with the breakthrough immunotherapy for advanced muscle-invasive bladder cancer, no new therapy has shown efficacy for non-muscle invasive disease unresponsive to BCG treatment. Kamat et al recently constructed guidelines on clinical trial design, defining BCG-unresponsive disease, as well as proposing therapeutic goals for conservative therapies in the BCG-unresponsive setting. This study is an extension of the ongoing effort to treat high risk, recurrent NMIBC while preserving the bladder. The investigators used a novel replication selective oncolytic adenovirus CG0070, which destroys bladder tumor cells through their defective retinoblastoma pathway. In this interim analysis of 36 patients, overall 6 month CR rate was 44%. The highest response rates were seen in pure CIS, while those with pure T1 disease or mixed CIS and Ta/T1 papillary disease had the worst outcomes. The therapy is relatively safe, with no grade 4/5 complications reported to date. Final results from this trial are eagerly awaited.
Presenter: Vignesh Packiam
Written By: Roger Li MD Urologic Oncology Fellow, UT MD Anderson Cancer Center @UrogerliMD
Ashish M. Kamat MD Wayne B. Duddlesten Professor, UT MD Anderson Cancer Center
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA